A new study reveals a groundbreaking blood test capable of predicting the onset of Alzheimer's disease symptoms within a few years. This plasma biomarker model, utilizing %p-tau217 levels, offers a more accessible and scalable alternative to costly imaging methods.
The research, conducted across two independent cohorts, constructed clock models to estimate the age of %p-tau217 positivity. These models demonstrated a significant association with the actual age of Alzheimer's symptom onset, with a median error of just 3.0 to 3.7 years. Notably, the time between biomarker positivity and symptom development was shorter in older individuals.
Findings were consistent across multiple immunoassay platforms, underscoring the robustness and reproducibility of plasma p-tau217 timing estimates. While further validation is needed, this blood test holds promise as a practical tool for clinical trials and potentially future clinical practice, aiding in the staging and enrollment for prevention-focused research.